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Abstract: Exercise-induced reactive oxygen and nitrogen species are increasingly considered as
beneficial health promotion. Astaxanthin (ASX) has been recognized as a potent antioxidant suitable
for human ingestion. We investigated whether ASX administration suppressed antioxidant enzyme
activity in moderate-intensity exercise. Seven-week-old male C57BL/6 mice (n = 8/group) were
treated with ASX (5, 15, and 30 mg/kg BW) combined with 45 min/day moderate-intensity swimming
training for four weeks. Results showed that the mice administrated with 15 and 30 mg/kg of ASX
decreased glutathione peroxidase, catalase, malondialdehyde, and creatine kinase levels in plasma or
muscle, compared with the swimming control group. Beyond that, these two (15 and 30 mg/kg BW)
dosages of ASX downregulated gastrocnemius muscle erythroid 2p45 (NF-E2)-related factor 2 (Nrf2).
Meanwhile, mRNA of Nrf2 and Nrf2-dependent enzymes in mice heart were also downregulated
in the ASX-treated groups. However, the mice treated with 15 or 30 mg/kg ASX had increased
constitutive nitric oxidase synthase and superoxide dismutase activity, compared with the swimming
and sedentary control groups. Our findings indicate that high-dose administration of astaxanthin
can blunt antioxidant enzyme activity and downregulate transcription of Nrf2 and Nrf2-dependent
enzymes along with attenuating plasma and muscle MDA.
Keywords: astaxanthin; antioxidant; oxidative stress; chronic exercise; physical adaption
1. Introduction
For decades, regular, nonexhaustive physical exercise has been considered beneficial for improving
health and physical fitness. Many studies show that chronic physical exercise can prevent several
chronic diseases (e.g., cardiovascular disease, diabetes, cancer, hypertension, obesity, depression, and
osteoporosis) and premature death. However, during high-intensity exercise, reactive oxygen and
nitrogen species (RONS) are yielded simultaneously, which may damage important macromolecules
such as lipids, protein, and DNA [1,2]. That said, organisms have evolved complicated endogenous
antioxidant defense mechanisms to minimize the potential damage caused by increased oxidative
stress [3]. Key antioxidant enzymes, such as glutathione peroxidase (GPx), superoxide dismutase
(SOD), and catalase (CAT), synergistically eliminate damaging free radical species. Two nuclear
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factors, erythroid 2p45 (NF-E2)-related factor 2 (Nrf2) and kelch-like ECH-associated protein 1 (Keap1),
regulate the transcription of phase II detoxifying enzymes in accordance with oxidative stress, thereby
maintaining cellular homeostasis in vivo [4,5]. Many Nrf2-dependent antioxidant enzymes, which have
antioxidant-response elements (AREs) in untranslated gene regions, are activated by Nrf2. These enzymes
embrace glutamate-cysteine ligase catalytic subunit (GCLC) and glutamate-cysteine ligase modifier
subunit (GCLM), which are the first-rate limiting enzymes of glutathione synthesis [6,7]; NAD(P)H
quinone dehydrogenase 1 (NQO-1), which prevents the one-electron reduction of quinones [8]; Heme
oxygenase 1 (HMOX-1), which cleaves heme to form biliverdin [9]. Although an overabundance of
RONS, generated within cells, can be counterproductive and overwhelm the endogenous antioxidant
defense system, an optimal amount of RONS produced during exercise can be beneficial for exercise
adaption and overall health [10–12]. Over the years, many studies have shown that oral administration
of vitamin C or vitamin C and E complex decreases muscle mitochondrial biogenesis and hampers
physical adaptations in endurance performance [13–17]. However, other studies have shown that
antioxidant treatment does not eliminate the beneficial effects of exercise [18–22]. Therefore, the
benefits of antioxidant supplementation in exercise training have become a controversial topic.
Astaxanthin (ASX) is a xanthophyll carotenoid, which is a fat-soluble red pigment found in
several species, such as microalgae, crustacea, fish, and birds [23]. According to the previous studies,
ASX can directly scavenge peroxyl (ROO•), alkoxyl (RO•), and singlet oxygen in a dose-dependent
way, but does not directly affect transcription of antioxidant enzymes [24]. Many other studies have
documented that dietary consumption of ASX can prevent or reduce the risk of various medical
conditions in humans and animals [25]. In addition, long-term supplementation of ASX in mice also
delays time to exhaustion during exercise [26–30]. Hence, ASX is considered a potent antioxidant
utilized as a nutritional supplement for physical exercise participants [31]. Nevertheless, previous
studies have revealed that antioxidant supplementation can blunt the expression of antioxidant
enzymes; this may decrease muscle adaption capability following exercise [16,17]. As such, it is our
contention and hypothesis that ingestion of high doses of the antioxidant ASX may blunt antioxidant
enzymes in vivo during bouts of regular physical exercise. Therefore, the purpose of this study was to
investigate the relationship between antioxidant status and the dosage of ASX supplementation using
a moderate-intensity exercise mouse swimming model.
2. Materials and Methods
2.1. Astaxanthin Source, Animals, and Experimental Design
Astaxanthin samples (Cat. No. SML 0982) were purchased from Sigma-Aldrich Co. LLC (Saint
Louis, MO, USA) and dissolved in olive oil, which was prepared in advance and stored at −20 ◦C.
Forty male C57BL/6 mice (7 weeks old) with weights ranging from 20~25 g were obtained from the
Experimental Animal Centre of Zhejiang Province, China, and four mice in each cage were housed
in the Animal Centre of Ningbo University College of Medicine (Ningbo, China). All mice were
acclimatized for one week in an air-conditioned (22 ± 2 ◦C and approximately 60% RH) room under a
12 h light/dark cycle (lights on from 07:30 to 19:30 h) with food and water provided ad libitum. The
composition of mouse feed is listed in a Supplementary Materials.
The mice were randomly divided into five groups, consisting of a sedentary control (SEC) group, a
swimming control (SWC) group, and three swimming plus ASX (SA) groups; each group was assigned
eight mice. For eliminating the background effect of olive oil acting on mice, the mice in the SEC and
SWC groups were orally administered 0.1 mL of olive oil by gavage each day. The mice in the three SA
groups were orally treated with 0.1 mL of the mixture of ASX and olive oil by gavage and participated
in a supplementation regime with dosages of ASX 5 mg/kg Body Weight (BW; SA5), 15 mg/kg BW
(SA15), and 30 mg/kg BW (SA30), respectively. The supplemented quantity of ASX was based on
published work [26,28]. However, some modifications were made for evaluating ASX concentrations
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in larger quantities during this experiment. All the mice were fed with an ASX mixture or olive oil two
hours prior to the initiation of swimming training.
The mice swimming model was based on previous research with slight modifications [32,33]. The
mice in the swimming groups performed chronic swimming training in a heated water tank (31 ± 2 ◦C),
five times a week for four weeks. No weight loads were used. During the four-week training period,
the durations of the swimming tasks were gradually increased from an initial 10 min/time to a final
level of 45 min/time, with an increasing duration of 5 min. After four weeks of training, all experimental
mice were sacrificed at 24 h postexercise (Figure 1). The experimental protocol used was in accordance
with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals and
approved by the Ethical Committee of Animal Use and Protection at Ningbo University Health Science
Centre. The handling of animals was also in accordance with the consensus author guidelines on
animal ethics.
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2.2. Sample Collection and Preparation
Blood samples were immediately collected from an eye socket vein and preserved in EDTA-tubes.
The blood samples were centrif ged at 3000× g fo 5 min, and the plasma aliquots w re subsequently
stored at −80 ◦C for biochemical analysis (enzyme activity and lipid peroxidation). The gastrocnemius
muscles of the mice were isolated immediately, and each one was divided into two portio s. One
portion, us d for total RNA xtractio , was immersed in RNAlater reagent (Cat. No. AM7020, Ambion,
city, country) and stored at −20 ◦C after one-night equilibration at 4 ◦C. The oth portion was wrapped
in luminum foil and stored at −80 ◦C. The gastrocnemius muscle tissue u ed for the det rmination of
enzyme activity or lipid peroxidation was homogenized in saline in n ic bath. Th h mogenated
samples were centrifuged at 3500× g for 10 min and the supernatants were pl ced into new EP tubes
and immediately t red at −80 ◦C for future analysis.
2.3. Antioxidant Enzymes and Malondialdehyde Assays
Total superoxide dismutase (SOD) activity in plasma was d termined using a sup roxide dismutase
(SOD) assay kit (Cat. No. A001-3, Nanjing Jiancheng Biotech Company, Nanjing, China). The
gl tathione peroxidase (GPx) activity both in plasma and muscle was assayed using a glutathione
peroxidase assay kit (Cat. No. A005, Nanjing Jiancheng Bio ch Company). Catalase (CAT) activity
in muscle was measured using a c talase assay kit (Cat. No. A007-1, Nanjing Jianche g Biotech
Company). Mal dialdehyde (MDA) conc ntrations in plasma or muscle tissue were obtained using a
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Microscale malondialdehyde assay kit (Cat. No. A003-2, Nanjing Jiancheng Biotech Company). All
assays were performed and completed following the manufacturer’s instructions.
2.4. Nitric Oxide Synthase and Creatine Kinase Assays
Plasma nitric oxide synthase activity was assayed using the Nitric Oxide Synthase typed assay kit
(Cat. No. A014, Nanjing Jiancheng Biotech Company). The kit was used to quantify total nitric oxide
synthase (tNOS), inducible nitric oxide synthase (iNOS), and constitutive nitric oxide synthase (cNOS)
activity. cNOS activity was calculated by the value of tNOS subtracted by that of iNOS. Plasma creatine
kinase (CK) activity was measured by a creatine kinase assay kit (Cat. No. A032, Nanjing Jiancheng
Biotech Company). All assays were conducted in accordance with the manufacturer’s instructions.
2.5. Analysis of Nrf2 and Nrf2-Dependent Gene Transcription in Gastrocnemius and Heart
Total RNA was extracted from the gastrocnemius muscle or heart from different groups using
TransZol Up Plus RNA Kit (Cat.No. ER501, Tansgen Biotech, Beijing, China), following the manufacturer’s
instructions. Two micrograms of each total RNA sample aliquot was treated with RNase free DNase I
(Takara, Dalian, China) and desalted before the first strand cDNA synthesis using RNeasy MinElute
Cleanup Kit (Cat.No. 74204, QIAGEN, Germany). The first-strand cDNA was synthesized using
HiFiScript gDNA Removal cDNA Synthesis kit (Cat.No. CW2582M, CWBIO, China). The quantitative
PCR was performed using TB Green Premix Ex Taq II kit (Takara, Japan). To evaluate PCR efficiency,
ten-fold serial dilutions of target gene plasmid cDNA, were used to create standard curves for each gene.
The specific primers (5′ to 3′) were GCTCCTATGCGTGAATCCCAA and TTTGCCCTAAGCTCATCTCGT
for Nrf2; CCATGTTCACCAACGGGCTTC and CGTGCAGGACACACTTCTCG for Keap1; TTCCCA
AATCAGCCCCGAT and TGCCATGTCAACTGCACTTCT for GCLM; TGCACATCTACCACGCAGTC
and ATCGCCTCCATTCAGTAACAAC for GCLC; ATGCTATGAACTTCAACCCCATC and TTCC
AGCTTCTTGTGTTCGG for NQO-1; CACATCCAAGCCGAGAATGC and GCTTGTTGCGCTCTAT
CTCC for HMOX-1; and ATCCGTAAAGACCTCTATGCC and CTCCTGCTTGCTGATCCAC for β-actin.
The PCR reaction system including 1 µL of cDNA, 0.4 µM of forward and reverse primers, and 10 µL
of TB Green Premix Ex Taq II, was finally adjusted to the required total volume of 20 µL by adding
RNase free water. The real-time PCR (Lightcycler 96, Roche, Switzerland) cycling conditions were
95 ◦C for 5 min, followed by 45 cycles of 95 ◦C for 10s, 59 ◦C for 10s, 72 ◦C for 10 s; (Roche, Switzerland).
Following amplification, the melting curves were tested by slowly heating from 60 ◦C to 95 ◦C in
increments of 0.5◦C/s. During this process, we used continuous fluorescence collection to confirm that
the peak signal was produced only from the target genes. Relative quantification methods (2ˆ-∆∆Ct)
were used to calculate the relative transcriptional level of each gene according to the Cycle threshold
value (Ct), in which the expression of Nrf2 and Keap1 genes was normalized against that of β-actin.
2.6. Statistical Analysis
Statistical analysis was performed using IBM SPSS Statistics version 22 (IBM, Armonk, NY, USA).
The values obtained from biological samples were analyzed using a one-way ANOVA, followed by
multiple comparisons using post hoc Tukey test. The homogeneity among different groups was analyzed;
if heterogeneity presented among the different groups, the Games–Howell model was utilized. Results
are expressed as mean ± standard deviation (SD) for the eight mice in each group (n = 8), or exhibited
as Box and Whisker plots, and values of p < 0.05 considered as statistically significant.
3. Results
3.1. Antioxidant Enzymes in Plasma or Muscle
Supplementation of ASX decreased plasma and skeletal muscle GPx and CAT, but increased
plasma SOD (Figure 2). It is suggested that supplementation of 15 mg and 30 mg/kg BW of ASX
decreased the plasma GPx activity in swimming training mice, compared with that in the SWC groups
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(p < 0.001 and p = 0.013, respectively) and SEC group (p < 0.001), However, the dose of 5 mg/kg BW
seemed not to affect GPx in the training mice, compared with the two higher dose groups (Figure 2A). In
addition, the muscle GPx activity of the SWC group was higher than that of the SEC groups (p = 0.005).
Meanwhile, the GPx activity in the SA5 and SA15 groups were higher than in the SEC group (p = 0.001,
and p < 0.001, respectively), and the activity in the SA30 group was significantly lower than that of
the SWC group (p = 0.002), and almost approached the level of the SEC groups (p = 0.711; Figure 2B).
In addition, it was observed that the CAT activity in the SWC group was higher than that of the
SEC group (p = 0.024), and supplementation of three different doses (5, 15, and 30 mg/kg BW) of
ASX decreased CAT level in the training mice, compared with the SWC group (p < 0.001; Figure 2C).
Meanwhile, the highest dose (30 mg/kg BW) of ASX significantly inhibited CAT activity, which was
lower than that observed in the SEC group (p = 0.014). However, the SOD activity among the different
groups demonstrated a gradually increasing trend (Figure 2D). It was suggested that the SOD activity
increased in the SA15 and SA30 groups, compared with the SEC and SWC groups (p < 0.05).
Nutrients 2019, 11, x FOR PEER REVIEW 5 of 13 
 
groups (p < 0.001 and p = 0.013, respectively) and SEC group (p < 0.001), However, the dose of 5 mg/kg 
BW seemed not to affect GPx in the training mice, compared with the two higher dose groups (Figure 
2A). In addition, the muscle GPx activity of the SWC group was higher than that of the SEC groups 
(p = 0.005). Meanwhile, the GPx activity in the SA5 and SA15 groups were higher than  in the SEC 
group (p = 0.001, and p < 0.001, respectively), and the activity in the SA30 group as significantly 
lower than that of the SWC group (p = 0.002), and almost approached the level of the SEC groups (p 
= 0.711; Figure 2B). In addition, it was observed that the CAT activity in the SWC group was higher 
than that of the SEC group (p = 0.024), and supplementation of three different doses (5, 15, and 30 
mg/kg BW) of ASX decreased CAT level in the training mice, compared with the SWC group (p < 
0.001; Figure 2C). Meanwhile, the highest dose (30 mg/kg BW) of ASX significantly inhibited CAT 
activity, which was lower than that observed in the SEC group (p = 0.014). However, the SOD activity 
among the different groups demonstrated a gradually increasing trend (Figure 2D). It was suggested 
that the SOD activity increased in the SA15 and SA30 groups, compared with the SEC and SWC 
groups (p < 0.05). 
 
Figure 2. Effects of astaxanthin on the GPx, CAT, and SOD activity in swimming training mice. (A) 
and (B) display GPx activity in plasma and gastrocnemius muscle among different groups, 
respectively. (C) exhibits CAT activity in gastrocnemius muscle among various groups, respectively. 
(D) shows SOD activity in plasma among different groups Values are means ± SD (n = 8). The symbol 
* indicates a significant difference at p < 0.05, and ** indicates a significant difference at p < 0.01. 
3.2. Plasma Malondialdehyde and Creatine Kinase and Muscle Nrf2-Keap1 Transcription 
Supplementation of ASX decreased MDA and CK levels in mice plasma or skeletal muscle and 
inhibited the transcriptional level of Nrf2 in gastrocnemius muscle (Figure 3). Both plasma and 
gastrocnemius MDA decreased in the SA15 and SA30 groups, compared with the SWC group (p < 
0.001) and the SEC group (p < 0.001). However, the group treated with 5 mg/kg BW of ASX was not 
shown to decrease plasma and gastrocnemius MDA, which were higher than that in the groups 
administrated with 15 and 30 mg/kg BW of ASX (p < 0.01; Figure 3A,B). Similarly, administration of 
ASX decreased the CK levels in swimming training mice (Figure 3C). Following mutiple comparison, 
the results showed that the groups supplemented with 5, 15, and 30 mg/kg BW of ASX decreased 
plasma CK value, compared with the SWC group (p = 0.031, p = 0.001, and p < 0.001, respectively). 
i 2. ff t t t i t , , and S activity in s i i trai i i .
(B) display GPx activity in plasma nd gastrocnemius muscle a ong different groups, respectively.
(C) exhibits CAT activity in gastrocnemius muscle among various groups, respectively. (D) shows SOD
activity in plasma among different gr ups Values are means ± SD (n = 8). The symbol * indicates a
significant difference at p < 0.05, and ** indicates a significant difference at p < 0.01.
3.2. Plasma Malondialdehyde and Creatine Kinase and Muscle Nrf2-Keap1 Transcription
Supplementation of ASX decreased MDA and CK levels in mice plasma or skeletal muscle and
inhibited the transcriptional level of Nrf2 in gastrocnemius muscle (Figure 3). Both plasma and
gastrocnemius MDA decreased in the SA15 and SA30 groups, compared with the SWC group (p < 0.001)
and the SEC group (p < 0.001). However, the group treated with 5 mg/kg BW of ASX was not shown to
decrease plasma and gastrocnemius MDA, which were higher than that in the groups administrated
with 15 and 30 mg/kg BW of ASX (p < 0.01; Figure 3A,B). Similarly, administration of ASX decreased
the CK levels in swimming training mice (Figure 3C). Following mutiple comparison, the results
showed that the groups supplemented with 5, 15, and 30 mg/kg BW of ASX decreased plasma CK
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value, compared with the SWC group (p = 0.031, p = 0.001, and p < 0.001, respectively). Meanwhile, the
CK value in the SA15 and the SA30 groups was lower than in the SEC group (p = 0.012 and p < 0.001,
respectively). In addition, the higher dose of ASX exhibited a greater inhibitory effect on CK and the
value in SA30 group was even lower than that of the SA5 group (p = 0.005).
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Additionally, supplementation of 15 or 30 mg/kg BW of ASX downregulated the transcriptional
level of Nrf2 by 41% and 39% in the gastrocnemius muscle, compared with the SWC group (p < 0.001;
Figure 3D). Meanwhile, the Keap1 level of three SA groups remained unchanged, compared with the
SWC groups (p > 0.05) but was higher than that of the SEC group (p = 0.029, p = 0.034 and p = 0.015,
respectively).
3.3. mRNA of Nrf2 and Nrf2-Dependent Enzymes in Heart
The mRNA level of Nrf2 in the SWC group elevated by 1.5-fold after exercise, compared with the
sedentary group (p = 0.036). The mRNA levels of Nrf2 in the SA15 and SA30 groups were shown to be
decreased, compared with the SWC group (p < 0.01; Figure 4A). Accordingly, the transcriptional level
of GCLM and GCLC was suggested to be decreased in astaxanthin supplement groups. It was observed
that the mRNA levels of GCLM among SA15 and SA30 groups significantly decreased, compared
with the SWC group (p < 0.01; Figure 4B). Meanwhile, the mRNA levels of GCLC among the SA5,
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SA15, and SA30 groups were significantly lower than the SWC and SEC groups (p < 0.05; Figure 4C).
Additionally, NQO-1 was inhibited as well after supplementation of astaxanthin. The mRNA level of
NQO-among the SA5, SA5, and SA30 groups significantly decreased, compared with the SWC group
(p < 0.01), meanwhile, the mRNA level in the SWC group was higher than the SEC group (p > 0.05;
Figure 4D). Meanwhile, the transcriptional level of HMOX-1 was significantly increased in the SWC
group, compared with the SEC group. Meanwhile, the level in the SA groups decreased in comparison
to the SWC group (Figure 4E)
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cNOS activity in all the three SA groups was higher than in the SEC group (p = 0.012, p = 0.004, and p 
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3.4. Plasma Nitric Oxide Synthase
We found that supplementation of ASX affected NOS level in plasma. It was demonstrated that
supplementation of 15 and 30 mg/kg BW of ASX increased the tNOS level in swimming training mice,
compared with the SEC group (p = 0.03 and p < 0.001, respectively; Figure 5A). It was also noted that as
the ASX dose proportionally increased, the cNOS activity among the different groups demonstrated an
increasing trend (Figure 5B). We found that only the group supplemented with 30 mg/kg BW of ASX
increased cNOS level, compared with the SWC group (p = 0.007). Meanwhile, the cNOS activity in all
the three SA groups was higher than in the SEC group (p = 0.012, p = 0.004, and p < 0.001, respectively).
In addition, as the ASX dose increased, the iNOS activity proportionately decreased (Figure 5C). The
results showed that the iNOS decreased in the SA30 group, compared with the SEC and SWC groups
(p = 0.035 and p = 0.044, respectively).
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4. Discussion
The primary finding from our work demonstrates that following administration of ASX and
moderate-intensity swimming training, high-dose ASX has the potential to suppress oxidative stress
and associated enzymatic antioxidants. There is now substantial evidence postulating that RONS are
essential signaling molecules driving cellular adaptations [34–38]. Indeed, recent work suggests that
exercise-induced oxidative stress may be a critical component for adaption to endurance training [39].
Our findings demonstrate that swimming training in mice treated with 15 mg or 30 mg/kg BW of
ASX decreases antioxidant activity and oxidative stress. Previous studies report that antioxidant
supplementation blunts the expression of key antioxidant enzymes and hampers exercise adaption.
According to Gomes-Cabrera et al., supplementation of 500 mg/kg BW of Vitamin C combined
with exercise training decreases the expression of Mn-SOD and GPx in mouse skeletal muscle and
significantly inhibited mitochondrial factors, including peroxisome proliferator-activated receptor
gamma coactivator 1-alpha (PGC-1α), Nuclear respiratory factor 1 (NRF-1), and mitochondrial
transcription factor A (MTF-A), and hampered endurance adaptions [16]. Similarly, Meier et al. found
that supplementation of an antioxidant cocktail (coenzyme Q10, 1% N-acetyl-cysteine, and vitamin
C) inhibited the expression of SOD, GPx, and CAT in skeletal muscle of exercise-trained mice [17].
Our findings suggest that supplementation of 15 or 30 mg/kg BW of ASX in mice performing the
moderate-intensity exercise significantly decreases in GPx and CAT activity in plasma or muscle.
Furthermore, we found that 15 and 30 mg/kg BW of ASX also decreased Nrf2 transcription in skeletal
muscle, but keap1 remained unchanged. This suggests that the expression of antioxidant enzymes is
perhaps suppressed partially via downregulation of the transcription of Nrf2. Because Nrf2 upregulates
the expression of antioxidant enzyme genes by acting on antioxidant response element (ARE) and
keap1 anchors Nrf2, which will be ubiquitinated and then decomposed [40,41]. Meanwhile, we also
observed that heart Nrf2 is downregulated in ASX-administrated groups. Moreover, Nrf2-dependent
genes GCLC and GCLM, which are the first-rate limiting enzymes of glutathione synthesis, were
also downregulated. Two studies showed that ASX supplementation increased the proportion of
glutathione (GSH) content in mice soleus muscle, which was considered as basal storage of antioxidative
capacity [29,42]. Although we did not quantify GSH in our study, we observed that mRNA of GCLC
and GCLM in heart decreased in the ASX-treated groups. The mRNA levels of both NQO-1 and
HMOX-1 also decreased in heart among the ASX-administrated groups in comparison to the SWC
group, suggesting the amount of quinones and hemes generated in heart are not necessary to trigger
the higher-level expression of NQO-1 and HMOX-1.
In addition, plasma SOD activity increased in the medium and high ASX dosage groups. The
plasma SOD is mainly composed of SOD3 (EC-SOD), which exerts an important protective role in
the vascular wall, and it was documented that the vasoactive factors such as histamine, vasopressin,
oxitocyn, endothelin-1, serotonin, and heparin markedly increased the enzyme level in cultured
arterial smooth muscle [43]. Previous report showed that SOD3 in alveolar type II pneumocytes was
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upregulated by TNF-α and INF-Υ through activation of nuclear factor Kappa-B (NF-κB). Further,
exercise training increases nitric oxide in mouse vessel endothelial cells, which in turn upregulates
expression of SOD3 in adjacent smooth muscle cells [44]. Meanwhile, ASX did not directly scavenge
superoxide anion free radicals [24]. The elevated concentration of SOD3 prevents the degradation
of NO by oxygen radicals. The nitric oxide system is a fundamental determinant of cardiovascular
homeostasis and regulates systemic blood pressure, vascular remodeling, and angiogenesis [45]. We
found the plasma constitutive NOS (cNOS) activity was increased in the SA30 group. The cNOS
consists of two isoforms: epithelial NOS (eNOS) and neuronal NOS (nNOS) [46], but in the plasma,
it is mainly composed of eNOS that are produced by epithelial cells [47]. Moncada et al., reported
that nitric oxide (NO) is an endothelium-derived relaxing factor, which contributed to the beneficial
effects of exercise on the cardiovascular system [48]. Furthermore, Sessa et al., has shown that chronic
exercise in dogs increased coronary vascular nitric oxide production and eNOS expression [49]. Other
studies in rats and humans have shown that nitric oxide contributes to glucose uptake and increased
skeletal muscle basal glucose disposal [50]. From the above studies, and in line with our data, we
concur that ASX can potentially stimulate eNOS activity, and this may facilitate vascular relaxation
or indeed contribute to improved recovery after chronic exercise. The increase in plasma iNOS can
also be considered as a marker of stimulated inflammatory status [51]. We observed a decrease
in iNOS following ASX supplementation in the swimming trained mice. Lee et al., revealed that
supplementation of ASX can prevent iNOS expression by blocking expression of proinflammatory
genes along with NF-κB [52].
Malondialdehyde (MDA) mainly results from lipid peroxidation of polyunsaturated fatty acids [53].
We observed that administration of 15 and 30 mg/kg BW of ASX significantly decreased plasma or
muscle MDA level but there were no significant effects on MDA level following the 5 mg/kg BW dose.
Other studies have shown that ASX supplementation can decrease MDA level in addition to blunting
antioxidant enzyme activity [29,42,54]. However, there were no substantial changes in MDA in both
the placebo and ASX groups in elite young soccer players after 90 days of supplementation [55].
The eﬄux of muscle CK is an indication of a change to normal membrane structure possibly
induced by muscle damage; this increased membrane permeability results in CK leakage into the
extracellular space [56]. A previous study suggested that chronic exercise increased CK level in mice
plasma [57]. In our study, we found that the CK activity agrees with the profile recorded for MDA.
Supplementation of three different dosages of ASX significantly decreased plasma CK, compared
with the swimming control group. Other studies provide evidence that ASX can decrease CK activity
in mice [26,57] or in humans [55,58]. Nevertheless, Richard et al., reported that supplementation
of 4 mg/day ASX in humans did not favorably affect CK values associated with skeletal muscle
injury following eccentric resistance strength training [59]. Klinkenberg et al., demonstrated that
supplementation of 20 mg/day ASX did not significantly decrease plasma CK in well-trained cyclists [60].
ASX is well defined as an efficient scavenger of ROO• and RO• radicals, which are reactive promoters of
lipid peroxidation [24]. Thus, ASX has the potential to inhibit lipid peroxidation on the cell membrane
and decrease oxidative stress following chronic exercise (as partially observed by the reduction in
MDA in our study).
In summary, 5 mg/kg BW of ASX supplementation did not reduce GPx and CAT activity, nor did
it suppress expression of Nrf2 in exercise trained mice. However, as the ASX supplemental dosages
were raised to 15 mg/kg BW and 30 mg/kg BW, it seemed to decrease the GPx and CAT level as
well as Nrf2 in the moderate-intensity swimming training mice. Therefore, using higher dosages of
ASX in moderate-intensity exercise may blunt the expression of antioxidant enzymes. However, in
high-intensity exercise, cells can generate an overabundance of RONS, and this may require a higher
production of antioxidants to neutralize and balance oxidative stress. This may be a potential reason
why there is a dosage-dependent relationship between duration time and ASX supplementation in
the exhaustive training mice [28]. In our view, the proper dosage used in exercise may optimize the
training effects by protecting against exercise-induced RONS overproduction; however, overdosed
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supplementation may impair the beneficial effects from exercise. Currently, the absorptivity of
astaxanthin between humans and mice is not widely studied, thus we cannot estimate the relative
amount for humans. The safe dosage used for human consumption has been discussed in a previous
review, and no adverse effects have been observed when humans were supplemented with dosages
ranging from 2.38 to 40 mg/day [61]. Nevertheless, the optimal dosage of ASX supplementation in
accordance with different oxidative stress for human health benefits needs further investigation in the
future. Finally, there are limitations of this study. Firstly, the physiological status of the exercising
animals was not measured due to a lack of appropriate equipment. Secondly, the effects of ASX on the
mice only receiving ASX treatment were not evaluated. Moreover, due to financial restrictions, we
did not collect a complete set of redox biology indices in tissue or plasma. Lastly, since antioxidant
enzymes are predominantly present and most active in the intracellular environment (i.e., CuZnSOD,
MnSOD), there may be a differential concentration between sites of determination (i.e., intracellular vs.
extracellular), and it is conceivable that the analytical kits have limitations in accurate plasma and
muscle quantification. Therefore, in any future investigation, protein levels of selected antioxidant
enzymes should be included to further evaluate the effects of ASX on exercise.
5. Conclusions
The findings from this study indicate for the first time that high dosage of astaxanthin suppresses
GPx and CAT activity in plasma or muscle in moderate-intensity training mice, and downregulates the
transcription of Nrf2 and Nrf2-dependent enzymes in skeletal muslce or heart, along with attenuating
plasma and muscle MDA.
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